MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Other EventsItem 8.01Other
On December 13, 2017, MiMedx Group, Inc. issued a press release announcing guidance for the year ended ended December 31, 2018. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.
Item 9.01Financial Statements and Exhibits
(d)Exhibits
MIMEDX GROUP, INC. ExhibitEX-99.1 2 a121320178-kex991.htm PRESS RELEASE Exhibit Exhibit 99.1 PRESS RELEASE CONTACT: MICHAEL SENKENPHONE: (770) 651-9100MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION Marietta,…To view the full exhibit click here
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.
